The article highlights Mirum Pharma's promising drug volixibat, which has shown superior interim data for PBC, making it a strong buy candidate. The company's financial stability, with a $2bn market cap and a substantial cash balance, supports this recommendation. The potential approval of volixibat in 2-3 years, along with existing approved products, provides a solid foundation for future growth.